UK markets closed

Hofseth BioCare ASA (0Q6H.L)

LSE - LSE Delayed price. Currency in NOK
Add to watchlist
2.1564-0.8536 (-28.36%)
At close: 12:47PM BST
Full screen
Loading interactive chart…
  • GlobeNewswire

    Hofseth Biocare ASA: HBC discovers new drug candidate for asthma and transfers it to HBC Immunology Inc.

    Ålesund, 02.07.24, Hofseth BioCare ASA ("HBC" or the "Company"), a global leader in marine lipid and peptide research, today announces the decision to transfer its eosinophil-targeting drug candidate MA-022a to its majority-owned subsidiary HBC Immunology Inc. ("HBCI"). The patent underlying the project has been valued by KWC AS at $4.5m (based on relief-from royalty method) and HBC will therefore receive 956,813 common shares in HBCI for the transfer of the patent to HBCI. HBC has booked approx

  • Globe Newswire

    Hofseth Biocare ASA: AGREES CHINA DISTRIBUTION PARTNERSHIP WITH SHANGHAI-BASED LITHY

    Hofseth BioCare ASA (HBC) is delighted to announce the appointment of Lithy One-Health Group Technology Co. Ltd (Lithy) as an additional distributor in China. Shanghai-based Lithy has entered into an agreement with HBC to distribute its science-led marine nutrition ingredients, ProGo® bioactive peptides, OmeGo® full spectrum omegas and CalGo® natural, undenatured type II collagen, to supplement manufacturers across the country. Lithy, which was established in 2002, has three subsidiaries that su

  • GlobeNewswire

    Hofseth Biocare ASA: FIRST QUARTER 2024 FINANCIAL REPORT

    The first quarter of 2024 continued on the positive trend for HBC. Sales revenues came in at NOK 52m vs NOK 44m last year, a growth of 17 % YoY. The underlying growth we are seeing is coming from both the ingredients business and finished products channels. The ingredients business continues to have solid demand growth especially for our core petfood products, and we have seen increased demand for our premium pure SPH product within this segment. We are also excited to have launched two new prod